Several state and federal efforts to reduce prescription drug costs have proposed using the Department of Veterans Affairs (VA) as a model, given its ability to obtain deep discounts on medications through direct negotiation with pharmaceutical manufacturers and the use of a national formulary. Published studies using data from a decade ago estimated that Medicare Part D could save $14 billion to $22 billion annually if it paid prices similar to those paid by the VA, [1] [2] [3] and a recent congressional report 4 for 20 brand-name drugs estimated potential annual savings of $2 billion. However, none of these estimates used actual prices paid by the VA, which can be lower than published federal prices. Thus, we used the most recent national data available from Medicare and the VA to quantify the savings Medicare Part D would achieve if it paid the same prices for prescription drugs currently paid by the VA.
Methods | We analyzed publicly available Medicare Part D prescription data from the Centers for Medicare & Medicaid Services between January 1, 2011, and December 31, 2016. 5 We obtained gross Medicare spending on each medication (defined based on the generic product name), quantity dispensed, and number of claims. We excluded drugs that had formulations other than capsules and tablets to accurately calculate perunit costs and limited our analyses to the top 50 oral drugs dispensed based on Medicare spending. This project using deidentified data was exempted from institutional review board approval by the Veterans Affairs St Louis Health Care System. To make Medicare and VA prescription spending comparable, we made 2 adjustments to Medicare spending. First, because publicly reported Medicare Part D data include patient payments and do not account for rebates, we discounted annual gross Medicare spending to account for these factors (eAppendix in the Supplement). Second, we subtracted a $2.50 dispensing fee for each Medicare claim because VA drug spending data do not include these costs. 6 After these adjustments, medication spending was divided by the number of units dispensed to establish a Medicare per unit cost.
Using the database of all prescriptions dispensed by the VA from 2011 to 2016, we identified all matches for the Medicare medications and obtained comparable data on acquisition costs and quantity dispensed using the actual price paid by the VA. We then applied the per unit costs from the VA to Medicare to calculate the amount that Medicare would spend annually if it obtained VA prices for the same quantity of medications. Discussion | To our knowledge, this is the most up-to-date analysis that directly compares prices between Medicare Part D and the VA, accounting for estimated rebates and using actual VA prices as opposed to publicly reported federal supply sched- ule prices. Using these data, we calculated $14.4 billion in potential savings in 2016 for only 50 drugs.
There are important limitations to this study. First, we did not differentiate between dosages or long-acting formulations when calculating unit prices, but most medications were brand-only products and were typically priced similarly regardless of dose. Second, it is unlikely that Medicare could capture the entirety of these savings, as VA prices could increase once Medicare obtained access, and Medicare would likely require a national formulary to leverage these reductions in price. However, our analysis of potential savings is conservative by studying only 50 drugs, omitting many high-cost medications with injectable formulations (eg, insulin and adalimumab), and focusing on price only without accounting for changes in use that could also lead to savings. The long-standing underrepresentation of women among medical academic leaders (deans, chairs, and professors) is well documented. However, little is known about trends in medical society leadership. Because tenure in society leadership positions contributes to academic advancement and provides opportunities to influence both the organization and the medical specialty, it is crucial to begin examining the demographics of society leadership.
Methods | In this cross-sectional study, we identified 1 major physician-focused medical society for each of the 43 specialty groupings listed in the 2016 Physician Specialty Data Report (Table) . 1 We generally selected the largest and/or most influential society in the field. Groupings for internal medicine/ pediatrics, neonatal-perinatal medicine, pediatric cardiology, and pediatric hematology/oncology (4 of 43 groupings) were then excluded because physicians in these specialties generally belong to the American Academy of Pediatrics (AAP). The primary outcome measures were years of presidential leadership attributed to men and women. To minimize some lack of independence across years, which is even greater for societies using 2-year presidential terms (4 of 39 societies; Table) , data were collected for a 10-year period (2008-2017), allowing for a minimum of 5 election cycles. For 38 societies, presidents' names were assigned to the year of election. For the AAP, which changed the start of its presidential term from fall to January in 2014, presidents elected before 2014 were assigned to the year following election. Gender was determined and verified via publicly available online profiles. Onesample tests of proportions comparing the percentage of women among association presidents with the percentage of women in active practice ( Figure) were used to determine the significance (2-sided P values) of underrepresentation or overrepresentation. [1] [2] [3] The Partners Human Research Commit- 
eAppendix. Methods
This supplementary material has been provided by the authors to give readers additional information about their work.
Medicare Part D data are available to the general public online from the Centers for Medicare and Medicaid Services (CMS). 1 It contains information about annual medication spending and utilization, but does not include cost information for individual dosages. Instead, it provides total spending for each medication aggregated to the active ingredient unit, broken down by year. Brand and generic versions are listed separately. Below is an example using atorvastatin data from 2016: Total Part D spending on atorvastatin calcium was $822 million, primarily for the generic product. Because these Part D prescription data do not account for rebates or third-party contributions and include beneficiary contributions, we used annual reports to Congress of net Medicare drug spending (the amount spent by the government, rather than total spending) to calculate the ratio of net-to-gross Medicare spending for all of Part D. 2 We then applied this ratio of net-to-gross spending (ranging from 79% in 2011 to 70% in 2016) to each medication in an effort to more accurately reflect true government spending and to make Part D spending more comparable to VA data. Medicare spending also includes both a dispensing fee and sales tax for the State of Illinois, neither of which are incorporated in VA spending. Thus, both were subtracted. A Brookings Institute report estimated $2.50 per claim for the dispensing fee, and a small percent was subtracted to account for the State of Illinois sales tax.
Brand
3,4 After these adjustments, total medication spending for a given generic name (e.g. Atorvastatin Calcium) was divided by the number of units dispensed to establish a unit cost for Medicare. An example calculation is presented below using the atorvastatin data: After calculating unit price in Medicare, net of rebates and dispensing fees, we calculated unit price in the Department of Veterans Affairs (VA) for the same drug product. All drug pricing data from the VA came from the Corporate Data Warehouse and reflects the most accurate unit prices at the time the medication was dispensed based on purchasing data from each site s respective wholesaler. To be consistent with Medicare data, we aggregated VA medication data regardless of dose, by generic product name, in the same fashion as the Medicare data. We then calculated VA unit cost, without any necessary adjustment for rebates, taxes, or dispensing fees, by simply dividing total spending by the total number of units for each medication.
For our calculations of Medicare spending with VA prices, we applied the VA unit price for each medication to the total number of units dispensed of that medication by Medicare. We then took the differenc M equaled potential savings for Medicare.
We excluded beneficiary cost/spending from our analysis for two reasons. First, VA data do not contain beneficiary cost sharing. Second, in Medicare, only average beneficiary cost data per medication is available. Without spending data for each individual beneficiary for all medications, and without knowledge of where they are in their coverage benefit (deductible, coverage gap, catastrophic spending level), we would likely inaccurately estimate beneficiary savings. Therefore, we included an adjustment (described above) to remove beneficiary spending from our calculation of prices.
Data Limitations
There are important limitations to the data. Specifically, the VA data do not have pricing information for brand and generic medications separately, and Medicare data did not have pricing information for specific dosages. As such, we could not compare generic and brand price differences among data sets, or dose-specific pricing differences. However, because we focus on medications with the highest Medicare spending, the majority of medications included were brand products where no generic was available; typically, among brand products there is little price difference across doses. Also, for the 2016 data as an example, there were only seven medications with long acting or additional brand formulations of the generic product. We believe it is unlikely that there is a large discrepancy between dosages and formulations for the two populations that would accrue substantial cost differences. As a result, the impact of these limitations is likely small. Still, we believe our analysis was conservative. We only examined the top 50 capsule and tablet-only medication formulations, excluding many high cost items like insulin and injectable outpatient biologic medications. When adjusting Medicare spending (including an adjustment for rebates), we averaged the total discount percentage for all medications, and applied this to each drug. The adjustment that we calculated and applied was between 21-35%, while CMS website for 2014 was only 17.5%.
